BioSpace News Archive

Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has taken action to improve the Company’s balance sheet through two separate transactions.

Shineco, Inc. announced the Company, through its wholly owned subsidiary Beijing Tenjove NewHemp Biotech Co., Ltd., has entered into a strategic cooperation agreement with Wuchang Municipal Government of Heilongjiang Province on December 18, 2019.

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), or the Company, announced today it is entering into an agreement with funds affiliated with an institutional investor providing for a private placement exempt from the registration requirements of the Securities Act of 1933, as amended, pursuant to which Idera has sold shares of Series B1 convertible preferred stock and warrants to purchase common stock for aggregate gross proceeds of $3.9 million

The cancer treatment industry has grown to be one of the largest marketplaces in the world due to the disease’s global prevalence

Invicro LLC, a Konica Minolta company, today announces, Dr. Matthew Silva has been appointed as the new Chief Executive Officer. Dr. Silva will assume the day-to-day leadership responsibilities of the Company and will join Invicro’s Board of Directors, effective immediately.

The American Diabetes Association’s 2020 Standards of Medical Care in Diabetes now include FDA-authorized artificial intelligence systems that detect diabetic retinopathy and macular edema

This News Release Is Intended for Distribution in Canada Only and Is Not Intended for Distribution to United States Newswire Services or Dissemination in the United States

Health Canada is advising Canadians, particularly parents and caregivers, that Taro Pharmaceuticals Inc. is recalling one lot of Atoma-brand Diphenhydramine Hydrochloride 2% Anti-Itch Cream because of a labelling error that may pose serious health risks to children under two years of age..

Illumina, Inc. announced that its executives will be speaking at the following investor conference and invite investors to participate via webcast.